The Food and Drug Administration removed a partial hold on Geron Corp.'s (Nasdaq: GERN) clinical trial of its myelofibrosis treatment imetelstat lifting the stock price 54 cents to close at $3.15.
Partial hold removed on Geron's imetelstat
June 12, 2014 at 18:51 PM EDT
